Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates
Phase I/II Randomized Clinical Trial of Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates
Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III
A PHASE1/PHASE2 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Centro Nacional de Investigaciones Oncologicas CARLOS III and has accumulated 7 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Feb 2020 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Oct 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centro Nacional de Investigaciones Oncologicas CARLOS III
- Grupo Espanol de Investigacion del Cancer de Mama
- Hospital Universitari de Bellvitge
- Hospital Universitario de Fuenlabrada
- M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .